Neuphoria Therapeutics Inc.
NEUP
$4.67
$0.081.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.99M | 15.65M | 15.65M | 15.66M | 662.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.99M | 15.65M | 15.65M | 15.66M | 662.70K |
| Cost of Revenue | -3.64M | -3.64M | -3.64M | -4.71M | -5.12M |
| Gross Profit | 18.62M | 19.29M | 19.29M | 20.37M | 5.79M |
| SG&A Expenses | 7.50M | 7.99M | 7.79M | 8.10M | 7.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.85M | 18.56M | 16.48M | 16.13M | 15.50M |
| Operating Income | -1.86M | -2.91M | -829.10K | -470.60K | -14.84M |
| Income Before Tax | -6.08M | -9.84M | -838.00K | 5.59M | -8.35M |
| Income Tax Expenses | -417.40K | -371.00K | -468.40K | -235.90K | -138.30K |
| Earnings from Continuing Operations | -5.66 | -9.47 | -0.37 | 5.83 | -8.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.66M | -9.47M | -369.60K | 5.83M | -8.21M |
| EBIT | -1.86M | -2.91M | -829.10K | -470.60K | -14.84M |
| EBITDA | -1.20M | -2.25M | -166.30K | 192.20K | -14.17M |
| EPS Basic | -2.12 | -3.77 | 0.03 | 1.35 | -8.04 |
| Normalized Basic EPS | -1.37 | -2.55 | -0.24 | -0.99 | -6.82 |
| EPS Diluted | -3.31 | -4.33 | -0.53 | 0.79 | -8.60 |
| Normalized Diluted EPS | -1.37 | -2.55 | -0.24 | -0.99 | -6.82 |
| Average Basic Shares Outstanding | 10.40M | 7.44M | 6.50M | 5.40M | 4.66M |
| Average Diluted Shares Outstanding | 10.40M | 7.44M | 6.50M | 5.40M | 4.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |